The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Pamidronate Treatment of Severe Osteogenesis Imperfecta in Children under 3 Years of Age
Open accessAbstract
Severe osteogenesis imperfecta (OI) is a hereditary disorder characterized by increased bone fragility and progressive bone deformity. Cyclical pamidronate infusions improve clinical outcome in children older than 3 yr of age with severe OI. Because earlier treatment may have potential to prevent deformities and improve functional prognosis in young children, we studied nine severely affected OI patients under 2 yr of age (2.3-20.7 months at entry) for a period of 12 months. Pamidronate was administered i.v. in cycles of 3 consecutive days. Patients received four to eight cycles during the treatment period, with cumulative doses averaging 12.4 mg/kg. Clinical changes were evaluated regularly during treatment, and radiological changes were assessed after 6-12 months of treatment. The control group consisted of six age-matched, severely affected OI patients, who had not received pamidronate treatment. During treatment bone mineral density (BMD) increased between 86-227%. The deviation from normal, as indicated by the z-score, diminished from -6.5 +/- 2.1 to -3.0 +/- 2.1 (P < 0.001). In the control group the BMD z-score worsened significantly. Vertebral coronal area increased in all treated patients (11.4 +/- 3.4 to 14.9 +/- 1.8 cm2; P < 0.001), but decreased in the untreated group (P < 0.05). In the treated patients, fracture rate was lower than in control patients (2.6 +/- 2.5 vs. 6.3 +/- 1.6 fractures/year; P < 0.01). No adverse side-effects were noted, apart from the well known acute phase reaction during the first infusion cycle. Pamidronate treatment in severely affected OI patients under 3 yr of age is safe, increases BMD, and decreases fracture rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic heterogeneity in osteogenesis imperfecta.
Sillence, D. O., Senn, A., & Danks, D. M. (1979) · Journal of Medical Genetics · doi:10.1136/jmg.16.2.101 · Cited by 2,229
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Cyclic Administration of Pamidronate in Children with Severe Osteogenesis Imperfecta
Glorieux, F. H., Bishop, N. J., Plotkin, H., Chabot, G., Lanoue, G., & Travers, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391402 · Cited by 1,015
Self-citationLindsay, R., Nieves, J., Formica, C., Henneman, E., Woelfert, L., Shen, V., Dempster, D., & Cosman, F. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02342-8 · Cited by 749
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Metabolic Bone Disease and Clinically Related Disorders
(1998) · Elsevier eBooks · doi:10.1016/b978-0-12-068700-8.x5000-2 · Cited by 276
Devogelaer, J., Malghem, J. J., Maldague, B., & de Deuxchaisnes, C. N. (1987) · Skeletal Radiology · doi:10.1007/bf00350961 · Cited by 139
Lumbar bone mineral content measured by dual energy X‐ray absorptiometry in newborns and infants
Salle, B. L., Braillon, P. M., Glorieux, F. H., et al. (1992) · Acta Paediatrica · doi:10.1111/j.1651-2227.1992.tb12152.x · Cited by 122
Osteogenesis imperfecta: A clinical study of the first ten years of life
Vetter, U. K., Pontz, B. F., Zauner, E., Brenner, R. E., & Spranger, J. W. (1992) · Calcified Tissue International · doi:10.1007/bf00297295 · Cited by 113
PTH: A future role in the management of osteoporosis?
REEVE, J. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110404 · Cited by 97
Therapeutic strategy in Paget's disease of bone
Meunier, P. J., & Vignot, E. (1995) · Bone · doi:10.1016/8756-3282(95)00260-2 · Cited by 82
Long-term effects of clodronate on growing rat bone
Lepola, V., Hannuniemi, R., Kippo, K., Laurén, L., Jalovaara, P., & Väänänen, H. K. (1996) · Bone · doi:10.1016/8756-3282(95)00439-4 · Cited by 49
Cited by
Horwitz, E. M., Gordon, P. L., Koo, W. K. K., Marx, J. C., Neel, M. D., McNall, R. Y., Muul, L., & Hofmann, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132252399 · Cited by 1,650
Rauch, F., & Glorieux, F. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16051-0 · Cited by 1,167
Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment
Van Dijk, F. S., & Sillence, D. O. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36545 · Cited by 795
Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta
Horwitz, E. M., Prockop, D. J., Gordon, P. L., Koo, W. W. K., Fitzpatrick, L. A., Neel, M. D., McCarville, M. E., Orchard, P. J., Pyeritz, R. E., & Brenner, M. K. (2001) · Blood · doi:10.1182/blood.v97.5.1227 · Cited by 571
Rauch, F., Travers, R., Plotkin, H., & Glorieux, F. H. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215952 · Cited by 250
Self-citation
Metadata
- Authors
- Plotkin, H.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-05-01
- Volume
- 85
- Issue
- 5
- Pages
- 1846-1850
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2144386867
- Cited by
- 315
- References
- 12
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.